A5001183684- Glaucoma and retinal disorders
- Retinal Diseases and Treatments
- Corneal surgery and disorders
- Ocular Surface and Contact Lens
- Herpesvirus Infections and Treatments
- Proteoglycans and glycosaminoglycans research
- Corneal Surgery and Treatments
- Virus-based gene therapy research
- Intraocular Surgery and Lenses
- NF-κB Signaling Pathways
- Healthcare and Venom Research
- Pharmacological Effects of Natural Compounds
- Cervical Cancer and HPV Research
- Viral Infections and Immunology Research
- Orthopedic Surgery and Rehabilitation
- Optical Coherence Tomography Applications
- Cancer-related Molecular Pathways
- Ocular Diseases and Behçet’s Syndrome
- Adipokines, Inflammation, and Metabolic Diseases
- Retinal Development and Disorders
- DNA Repair Mechanisms
- Atherosclerosis and Cardiovascular Diseases
- Toxin Mechanisms and Immunotoxins
- Angiogenesis and VEGF in Cancer
- Cell death mechanisms and regulation
Allergan (United States)
2016-2025
AbbVie (United States)
2021-2025
Center for Devices and Radiological Health
2012
University of Miami
2009-2010
Foundation for the National Institutes of Health
2010
Prevent Blindness
2010
Research to Prevent Blindness
2010
Topcon (Netherlands)
2010
RR Donnelley (United States)
2010
Kessler Foundation
2010
PurposeTo evaluate the safety and intraocular pressure (IOP)-lowering effect of a biodegradable bimatoprost sustained-release implant (Bimatoprost SR).DesignPhase I/II, prospective, 24-month, dose-ranging, paired-eye controlled clinical trial.MethodsAt baseline following washout, open-angle glaucoma patients (n = 75) were administered Bimatoprost SR (6 μg, 10 15 or 20 μg) intracamerally in study eye; fellow eye began topical 0.03% once daily. Rescue IOP-lowering medication single repeat...
To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10- 15-μg bimatoprost implant in subjects with open-angle glaucoma (OAG) ocular hypertension (OHT) after initial repeated administrations.Randomized, 20-month, multicenter, subject- evaluator-masked, parallel-group, phase 3 clinical study.Adults OAG or OHT each eye, open iridocorneal angle inferiorly study eye baseline IOP (hour 0; 8 am) 22-32 mmHg washout.Study eyes received 10 μg (n = 198) 15 on day 1...
The objective of this study was to evaluate the safety and intraocular pressure (IOP)-lowering effects over 24 months biodegradable bimatoprost sustained-release implant (Bimatoprost SR) administration versus topical 0.03% in patients with open-angle glaucoma (OAG).This a phase I/II, prospective, 24-month, dose-ranging, paired-eye controlled clinical trial. At baseline following washout, adult OAG (N = 75) received Bimatoprost SR (6, 10, 15, or 20 µg) intracamerally eye; fellow eye once...
To evaluate the intraocular pressure (IOP)-lowering effect and safety of up to two bimatoprost implant administrations versus selective laser trabeculoplasty (SLT). Phase 3 (Stage 2), randomized, 24-month, multicenter, patient- efficacy evaluator-masked, paired-eye clinical trial (NCT02507687). Patients (n=183) with open-angle glaucoma or ocular hypertension inadequately managed topical IOP-lowering medication for reasons other than efficacy. received a single 360° SLT procedure in one eye...
To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10 15 µg bimatoprost implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial enrolled 528 OAG OHT an open iridocorneal angle inferiorly study eye. Study eyes were administered on day 1, week 16, 32, twice-daily topical timolol maleate 0.5%. Primary endpoints IOP change from baseline through 12. Safety measures...
ABSTRACT Wild-type herpes simplex virus type 1 (HSV-1) infection triggers apoptosis in human cells. The subsequent synthesis of infected cell proteins between 3 and 6 h postinfection (hpi) acts to block this process from killing the factors produced during window also prevent death induced by environmental staurosporine or sorbitol (M. Aubert, J. O'Toole, A. Blaho, Virol. 73:10359-10370, 1999). We now report that (i) prevention window, HSV-1(F) inhibited tumor necrosis factor alpha (TNF-α)...
PurposeMany patients with open-angle glaucoma eventually require >2 medications to lower their intraocular pressure (IOP). Fixed-combination ophthalmic solutions can be advantageous in who multiple medications, but the number of fixed combinations combining 3 complementary IOP-lowering agents remains limited. This study assessed efficacy and safety a triple combination (TFC) bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% solution primary (POAG) or ocular hypertension (OHT), compared dual...
To describe the clinical findings of hypotony maculopathy using 3-dimensional (3D) topography maps reconstructed from spectral domain optical coherence tomography (SD-OCT) imaging, and compare SD-OCT with time OCT (TD-OCT) for diagnosis.This was an observational noncomparative case series comprising 7 patients after trabeculectomy mitomycin-C. All underwent consecutive imaging TD-OCT (Stratus OCT) various high-resolution instruments. 3-D surface obtained were compared linear scans TD-OCT.Two...
Objective. To evaluate the efficacy and safety of triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC) versus dual brimonidine 0.2%/timolol (DFC) in primary open-angle glaucoma ocular hypertension. Methods. Patients with intraocular pressure (IOP) ≥23 ≤34 mmHg were randomized to twice-daily TFC or DFC. The variable is change worse eye mean IOP from baseline at week 12 (modified intent-to-treat (mITT) population). Secondary endpoints are weeks 1, 2, 4, 8, (mITT...
To assess the intraocular pressure (IOP)-lowering effect of a biodegradable bimatoprost implant following selective laser trabeculoplasty (SLT) in canine model.
purpose. Herpes simplex virus (HSV)-1 infections of the human cornea range in severity from uncomplicated episodes that readily resolve to severe, recurring disease invades stroma, having a devastating permanent effect on vision. Recent published data implicate an apoptotic component stromal HSV-1 infection. In prior study, it was found wild type (wt) infection induces, then blocks, apoptosis epithelial cells derived skin and this block requires infected cell proteins (ICPs) synthesized...
Purpose: Fixed-combination medications can benefit patients requiring multiple agents to lower their intraocular pressure (IOP), but combining with complementary mechanisms of action is challenging if dosing frequency differs. This study compares in vivo pharmacokinetic and ocular tolerability bimatoprost 0.01% ophthalmic solutions dosed once or twice daily. Reports twice-daily glaucoma are also reviewed. Methods: New Zealand White rabbits were administered monotherapy fixed-combination...
Sustained-release intraocular implants provide a therapeutic option for open-angle glaucoma (OAG) and ocular hypertension (OHT) patients who are non-compliant with eyedrops. Currently, there no published patient-reported outcome (PRO) measures that assess treatment satisfaction implants. To address this gap, new PRO instrument, the Allergan Satisfaction Treatment Experience Questionnaire (ASTEQ), has been developed in accordance Food Drug Administration guidance. Qualitative research...
Introduction: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of a triple fixed-combination bimatoprost, brimonidine, timolol (TFC) in patients with glaucoma or ocular hypertension (OHT) treated unfixed brimonidine therapy (dual-combination therapy). Methods: In this multicenter, open-label, phase 3 study, who received 4– 8 weeks dual-combination twice daily had an IOP > 18 < 34 mmHg at least one eye were switched (at baseline) to treatment TFC for 12 weeks. At Weeks...
Abstract Purpose Selective Laser Trabeculoplasty (SLT) is a treatment for lowering intraocular pressure (IOP) in patients with glaucoma, however IOP‐lowering not sustained after SLT over long term substantial proportion of patients. Recent human studies found less reduction IOP when and topical prostaglandin analogues (PGA) were used combination. Bimatoprost Sustained Release (BimSR) implant currently development as an agent delivered intracamerally (IC). The purpose this study was to assess...
Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort®, Allergan, an AbbVie company) effectively reduces intraocular pressure (IOP) via complementary mechanisms of action the agents, but long-term (> 12 weeks) safety evaluations FCBT remain limited. is evaluated herein, with particular focus on hyperemia and eyelash growth, at 24 weeks in Chinese patients open-angle glaucoma (OAG) or ocular hypertension (OHT).In this multicenter, open-label, noncomparative,...